Downcoded

Your TAVR Denials Since September Will Not Fix Themselves

Medicare stopped requiring a clinical trial and a second surgeon on transcatheter aortic valve replacement effective September 10. The contractors were told today, the edits come off April 5, and CMS has instructed them not to go back and look.


Medicare's instruction to its claims contractors on transcatheter aortic valve replacement went up on the transmittal index this morning. Change Request 14657, two transmittals, both numbered 14047, one for the coverage manual and one for claims processing.

The effective date on both cover pages reads September 10, 2026. The implementation date reads April 5, 2027.

So the coverage changed 70 days ago, the contractors found out today, and the edits that contradict the new policy stay switched on for another 137.

What Came Out of NCD 20.32

CMS closed the reconsideration, CAG-00430R2, on September 10. The version of NCD 20.32 that it replaced had been in force since June 21, 2019, which is 2,638 days.

The Medicare Coverage Database is still serving that old version tonight. Query NCD 355 and you get version 2, last updated 08/16/2023, effective 06/21/2019, with every volume floor intact. There is no version 3.

The new manual text is only in today's transmittal. Here is what left:

  • Coverage with evidence development for symptomatic severe aortic stenosis. It is now covered under §1862(a)(1)(A), plain and simple, with no trial, no Z00.6, no modifier Q0 and no NCT number.
  • Every hospital volume floor. The 2019 policy required a program to maintain at least 50 aortic valve replacements a year including 20 TAVRs, or 100 every two years including 40 TAVRs, plus two physicians with cardiac surgery privileges, one interventional cardiologist and 300 PCIs a year. All of it is gone. The hospital criteria now run to three bullets: on-site structural heart interventional cardiology and cardiac surgery programs, a post-procedure ICU, and a continuous quality improvement process.
  • The registry. Participation in a prospective, national, audited registry was a condition of payment. It is not any more.
  • The career-volume qualifications for the surgeon and the interventionalist, replaced by an operator-level test: 20 transcatheter valve procedures a year of which 15 are TAVR, or 40 every two years of which 30 are TAVR.
  • The national non-coverage rule. The old policy carved out patients whose comorbidities would preclude benefit. The Nationally Non-Covered Indications section now reads, in full, "N/A".

And the line that moves money on the professional side, verbatim:

"Joint participation of two TAVR operators in a TAVR procedure is not required but may occur if determined appropriate by the heart team."

Asymptomatic severe AS comes in the other direction, covered under CED in a CMS-approved study approved on or after September 10. The ACC's read is that no such study exists yet. At the claim level that is the same as no change.

The rest of this brief is for subscribers.

The impact tables, the code-level detail, and the rest of the analysis sit past this line.

$50 a month, or $500 a year.